Patent application number | Description | Published |
20090197823 | ALISKIREN MODULATION OF NEUROGENESIS - The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of a renin inhibitor in combination with one or more neurogenic agents. The disclosure also includes compositions and methods for stimulating or activating the formation of new nerve cells based on the application of a renin inhibitor in combination with one or more neurogenic agents. | 08-06-2009 |
20090239834 | MCC-257 MODULATION OF NEUROGENESIS - The disclosure provides methods and a composition for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of (5-acetamido-N-(5alpha-cholestan-3alpha-yl)-3,5-dideoxy-2-O-methyl-D-glycero-alpha-D-galacto-non-2-ulopyranosonamide(MCC-257). The disclosure also includes methods and a composition for stimulating or activating the formation of new nerve cells based on the application of MCC-257 | 09-24-2009 |
20090325949 | 5 HT RECEPTOR MEDIATED NEUROGENESIS - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells. | 12-31-2009 |
20100009983 | 5 HT RECEPTOR MEDIATED NEUROGENESIS - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or activate the formation of new nerve cells. | 01-14-2010 |
20100120842 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells. | 05-13-2010 |
20100184806 | MODULATION OF NEUROGENESIS BY PPAR AGENTS - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a nervous system disease or disorder. | 07-22-2010 |
20100216734 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use nootropic agents, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells. | 08-26-2010 |
20100216805 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS - The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure provides compositions and methods based on the use of D-cycloserine in combination with the neurogenic agent, which synergistically stimulates or activates the formation of new nerve cells. | 08-26-2010 |
20110046090 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent or GABA analog, in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells. | 02-24-2011 |
20110092464 | NEUROGENESIS BY MODULATING ANGIOTENSIN - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells. | 04-21-2011 |
20110269717 | NEUROGENESIS BY MODULATING ANGIOTENSIN - The instant invention describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells. | 11-03-2011 |
20110319386 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells. | 12-29-2011 |